Income generated from the University of Cambridge’s commercialisation activities continued to rise in 2011, as did the number of intellectual property, consultancy and equity agreements signed on behalf of the University and its researchers.
Income generated from the University of Cambridge’s commercialisation activities continued to rise in 2011, as did the number of intellectual property, consultancy and equity agreements signed on behalf of the University and its researchers.
The growth enjoyed by Cambridge Enterprise this year demonstrates the value that industry attaches to Cambridge research, and the contribution the University is making to our national economic recovery.
Tony Raven
Cambridge Enterprise, the University’s commercialisation group, has recently announced its year-end results. Income from licensing, consultancy and equity transactions exceeded £10.2 million, with £8.3 million of that amount returned to the University, departments and researchers.
Cambridge Enterprise currently provides support to more than 1,000 University researchers at all stages of the commercialisation process, from supporting grant proposals, to licensing technology to existing companies, through to funding new companies and ventures.
‘Universities such as Cambridge have an important role to play in supporting an innovation-led economic recovery, through collaborative research, technology licensing, consultancy projects and new company formation,’ said Dr Tony Raven, Chief Executive of Cambridge Enterprise. ‘The growth enjoyed by Cambridge Enterprise this year demonstrates the value that industry attaches to Cambridge research, and the contribution the University is making to our national economic recovery.’
Over the past year, the Cambridge Enterprise team completed 116 licences, signed 183 consultancy contracts and returned more than £468,000 to its evergreen seed funds through equity transactions. Income from licensing increased 24% from 2009/10, and income from consultancy increased by 37% year over year.
Cambridge Enterprise also invests intellectual property and cash to create new companies and ventures based on Cambridge research. Currently, Cambridge Enterprise holds equity in 68 companies and manages ‘evergreen’ seed funds on the University’s behalf. Over the past year, the companies in the Cambridge Enterprise portfolio raised more than £189 million in funding, including $200 million raised by Plastic Logic.
One of the fastest-growing companies in the portfolio is Eight19, which was spun-out from the Cavendish Laboratory in 2010. The company, which is building upon the Cavendish’s expertise in the area of organic photovoltaics, has recently completed trials of IndiGo, a personal pay-as-you-go solar electricity system, in Zambia, Kenya, Malawi and India. The system could provide safe, sustainable and affordable power for some of the 1.6 billion people worldwide who do not have access to electricity.
Another Cambridge company which enjoyed a highly successful year was PneumaCare, which has developed a non-contact method of measuring lung function for the one third of patients who are unable to use current methods. The company was named a winner at the prestigious Medical Futures Innovation Awards, and its product is now in use in hospitals across the UK, with expansion to southeast Asia and North America planned for 2012.
The 2011 Annual Review is available for download at www.enterprise.cam.ac.uk.
This work is licensed under a Creative Commons Licence. If you use this content on your site please link back to this page.
